CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV. Published in The Journal of Infectious Diseases, researchers at the University…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
